http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 26 Aug 2026 08:35:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celcuity+Inc.+++++++++++++For%3A+Aug+26/26977804.html si-local-file:///var/storage/secattach/20260826/26977804.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celcuity+Inc.+++++++++++++For%3A+Aug+26/26977804.html Wed, 26 Aug 2026 08:35:00 -0400 CELC O.34685291 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celcuity+Inc.+++++++++++++For%3A+Aug+26/26977804.html si-local-file:///var/storage/secattach/20260826/26977804.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celcuity+Inc.+++++++++++++For%3A+Aug+26/26977804.html Wed, 26 Aug 2026 08:35:00 -0400 CELC O.34685291 http://www.streetinsider.com/Corporate+News/Celcuity+files+sNDA+for+gedatolisib+in+PIK3CA+mutant+breast+cancer/26977785.html <p>Celcuity Inc. (Nasdaq: CELC) announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Revtorpyk (gedatolisib) to treat patients with hormone receptor positive, HER2-negative locally advanced or metastatic breast cancer with a PIK3CA mutation, following progression on at least one line of endocrine therapy.</p><p>The application is supported by results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial. In that cohort, the Revtorpyk-triplet regimen — gedatolisib combined with fulvestrant and palbociclib — reduced the risk of disease progression or death by 50% compared with alpelisib plus fulvestrant (HR=0.50; 95% http://www.streetinsider.com/Corporate+News/Celcuity+files+sNDA+for+gedatolisib+in+PIK3CA+mutant+breast+cancer/26977785.html Wed, 26 Aug 2026 08:32:16 -0400 CELC http://www.streetinsider.com/FDA/Celcuity+files+sNDA+for+gedatolisib+in+PIK3CA+mutant+breast+cancer/26977785.html <p>Celcuity Inc. (Nasdaq: CELC) announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Revtorpyk (gedatolisib) to treat patients with hormone receptor positive, HER2-negative locally advanced or metastatic breast cancer with a PIK3CA mutation, following progression on at least one line of endocrine therapy.</p><p>The application is supported by results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial. In that cohort, the Revtorpyk-triplet regimen — gedatolisib combined with fulvestrant and palbociclib — reduced the risk of disease progression or death by 50% compared with alpelisib plus fulvestrant (HR=0.50; 95% http://www.streetinsider.com/FDA/Celcuity+files+sNDA+for+gedatolisib+in+PIK3CA+mutant+breast+cancer/26977785.html Wed, 26 Aug 2026 08:32:16 -0400 CELC http://www.streetinsider.com/Press+Releases/Celcuity+Submits+sNDA+to+FDA+for+REVTORPYK%E2%84%A2+%28gedatolisib%29+for+HR%2BHER2-%2C+PIK3CA+Mutant+Locally+Advanced+or+Metastatic+Breast+Cancer/26977749.html <ul type="disc"><li><em>If approved, REVTORPYK would be the first and only therapy for advanced breast cancer with a PIK3CA mutation that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2</em><br/></li></ul> <p>MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth http://www.streetinsider.com/Press+Releases/Celcuity+Submits+sNDA+to+FDA+for+REVTORPYK%E2%84%A2+%28gedatolisib%29+for+HR%2BHER2-%2C+PIK3CA+Mutant+Locally+Advanced+or+Metastatic+Breast+Cancer/26977749.html Wed, 26 Aug 2026 08:30:00 -0400 A.06822034 CELC O.20026344 O.34685291 http://www.streetinsider.com/Press+Releases/Celcuity+Submits+sNDA+to+FDA+for+REVTORPYK%E2%84%A2+%28gedatolisib%29+for+HR%2BHER2-%2C+PIK3CA+Mutant+Locally+Advanced+or+Metastatic+Breast+Cancer/26977749.html <ul type="disc"><li><em>If approved, REVTORPYK would be the first and only therapy for advanced breast cancer with a PIK3CA mutation that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2</em><br/></li></ul> <p>MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth http://www.streetinsider.com/Press+Releases/Celcuity+Submits+sNDA+to+FDA+for+REVTORPYK%E2%84%A2+%28gedatolisib%29+for+HR%2BHER2-%2C+PIK3CA+Mutant+Locally+Advanced+or+Metastatic+Breast+Cancer/26977749.html Wed, 26 Aug 2026 08:30:00 -0400 A.06822034 CELC O.20026344 O.34685291 http://www.streetinsider.com/Press+Releases/Celcuity+Submits+sNDA+to+FDA+for+REVTORPYK%E2%84%A2+%28gedatolisib%29+for+HR%2BHER2-%2C+PIK3CA+Mutant+Locally+Advanced+or+Metastatic+Breast+Cancer/26977749.html <ul type="disc"><li><em>If approved, REVTORPYK would be the first and only therapy for advanced breast cancer with a PIK3CA mutation that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2</em><br/></li></ul> <p>MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth http://www.streetinsider.com/Press+Releases/Celcuity+Submits+sNDA+to+FDA+for+REVTORPYK%E2%84%A2+%28gedatolisib%29+for+HR%2BHER2-%2C+PIK3CA+Mutant+Locally+Advanced+or+Metastatic+Breast+Cancer/26977749.html Wed, 26 Aug 2026 08:30:00 -0400 A.06822034 CELC O.20026344 O.34685291 http://www.streetinsider.com/Press+Releases/Celcuity+Submits+sNDA+to+FDA+for+REVTORPYK%E2%84%A2+%28gedatolisib%29+for+HR%2BHER2-%2C+PIK3CA+Mutant+Locally+Advanced+or+Metastatic+Breast+Cancer/26977749.html <ul type="disc"><li><em>If approved, REVTORPYK would be the first and only therapy for advanced breast cancer with a PIK3CA mutation that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2</em><br/></li></ul> <p>MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth http://www.streetinsider.com/Press+Releases/Celcuity+Submits+sNDA+to+FDA+for+REVTORPYK%E2%84%A2+%28gedatolisib%29+for+HR%2BHER2-%2C+PIK3CA+Mutant+Locally+Advanced+or+Metastatic+Breast+Cancer/26977749.html Wed, 26 Aug 2026 08:30:00 -0400 A.06822034 CELC O.20026344 O.34685291 http://www.streetinsider.com/Globe+Newswire/Celcuity+Submits+sNDA+to+FDA+for+REVTORPYK%E2%84%A2+%28gedatolisib%29+for+HR%2BHER2-%2C+PIK3CA+Mutant+Locally+Advanced+or+Metastatic+Breast+Cancer/26977749.html <ul type="disc"><li><em>If approved, REVTORPYK would be the first and only therapy for advanced breast cancer with a PIK3CA mutation that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2</em><br/></li></ul> <p>MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth http://www.streetinsider.com/Globe+Newswire/Celcuity+Submits+sNDA+to+FDA+for+REVTORPYK%E2%84%A2+%28gedatolisib%29+for+HR%2BHER2-%2C+PIK3CA+Mutant+Locally+Advanced+or+Metastatic+Breast+Cancer/26977749.html Wed, 26 Aug 2026 08:30:00 -0400 A.06822034 CELC O.20026344 O.34685291 http://www.streetinsider.com/Globe+Newswire/Celcuity+Submits+sNDA+to+FDA+for+REVTORPYK%E2%84%A2+%28gedatolisib%29+for+HR%2BHER2-%2C+PIK3CA+Mutant+Locally+Advanced+or+Metastatic+Breast+Cancer/26977749.html <ul type="disc"><li><em>If approved, REVTORPYK would be the first and only therapy for advanced breast cancer with a PIK3CA mutation that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2</em><br/></li></ul> <p>MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth http://www.streetinsider.com/Globe+Newswire/Celcuity+Submits+sNDA+to+FDA+for+REVTORPYK%E2%84%A2+%28gedatolisib%29+for+HR%2BHER2-%2C+PIK3CA+Mutant+Locally+Advanced+or+Metastatic+Breast+Cancer/26977749.html Wed, 26 Aug 2026 08:30:00 -0400 A.06822034 CELC O.20026344 O.34685291 http://www.streetinsider.com/Globe+Newswire/Celcuity+Submits+sNDA+to+FDA+for+REVTORPYK%E2%84%A2+%28gedatolisib%29+for+HR%2BHER2-%2C+PIK3CA+Mutant+Locally+Advanced+or+Metastatic+Breast+Cancer/26977749.html <ul type="disc"><li><em>If approved, REVTORPYK would be the first and only therapy for advanced breast cancer with a PIK3CA mutation that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2</em><br/></li></ul> <p>MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth http://www.streetinsider.com/Globe+Newswire/Celcuity+Submits+sNDA+to+FDA+for+REVTORPYK%E2%84%A2+%28gedatolisib%29+for+HR%2BHER2-%2C+PIK3CA+Mutant+Locally+Advanced+or+Metastatic+Breast+Cancer/26977749.html Wed, 26 Aug 2026 08:30:00 -0400 A.06822034 CELC O.20026344 O.34685291 http://www.streetinsider.com/Globe+Newswire/Celcuity+Submits+sNDA+to+FDA+for+REVTORPYK%E2%84%A2+%28gedatolisib%29+for+HR%2BHER2-%2C+PIK3CA+Mutant+Locally+Advanced+or+Metastatic+Breast+Cancer/26977749.html <ul type="disc"><li><em>If approved, REVTORPYK would be the first and only therapy for advanced breast cancer with a PIK3CA mutation that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2</em><br/></li></ul> <p>MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth http://www.streetinsider.com/Globe+Newswire/Celcuity+Submits+sNDA+to+FDA+for+REVTORPYK%E2%84%A2+%28gedatolisib%29+for+HR%2BHER2-%2C+PIK3CA+Mutant+Locally+Advanced+or+Metastatic+Breast+Cancer/26977749.html Wed, 26 Aug 2026 08:30:00 -0400 A.06822034 CELC O.20026344 O.34685291 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Celcuity+Inc.+++++++++++++For%3A+Aug+14++Filed+by%3A+Laing+Lance+G./26944541.html si-local-file:///var/storage/secattach/20260818/26944541.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Celcuity+Inc.+++++++++++++For%3A+Aug+14++Filed+by%3A+Laing+Lance+G./26944541.html Tue, 18 Aug 2026 16:19:00 -0400 CELC O.34685291 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Celcuity+Inc.+++++++++++++For%3A+Aug+14++Filed+by%3A+Laing+Lance+G./26944541.html si-local-file:///var/storage/secattach/20260818/26944541.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Celcuity+Inc.+++++++++++++For%3A+Aug+14++Filed+by%3A+Laing+Lance+G./26944541.html Tue, 18 Aug 2026 16:19:00 -0400 CELC O.34685291 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Celcuity+Inc.+++++++++++++For%3A+Aug+14++Filed+by%3A+Hahne+Vicky/26944514.html si-local-file:///var/storage/secattach/20260818/26944514.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Celcuity+Inc.+++++++++++++For%3A+Aug+14++Filed+by%3A+Hahne+Vicky/26944514.html Tue, 18 Aug 2026 16:18:00 -0400 CELC O.34685291 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Celcuity+Inc.+++++++++++++For%3A+Aug+14++Filed+by%3A+Hahne+Vicky/26944514.html si-local-file:///var/storage/secattach/20260818/26944514.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Celcuity+Inc.+++++++++++++For%3A+Aug+14++Filed+by%3A+Hahne+Vicky/26944514.html Tue, 18 Aug 2026 16:18:00 -0400 CELC O.34685291 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Celcuity+Inc.+++++++++++++For%3A+Aug+14++Filed+by%3A+Sullivan+Brian+F./26944532.html si-local-file:///var/storage/secattach/20260818/26944532.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Celcuity+Inc.+++++++++++++For%3A+Aug+14++Filed+by%3A+Sullivan+Brian+F./26944532.html Tue, 18 Aug 2026 16:18:00 -0400 CELC O.34685291 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Celcuity+Inc.+++++++++++++For%3A+Aug+14++Filed+by%3A+Sullivan+Brian+F./26944532.html si-local-file:///var/storage/secattach/20260818/26944532.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Celcuity+Inc.+++++++++++++For%3A+Aug+14++Filed+by%3A+Sullivan+Brian+F./26944532.html Tue, 18 Aug 2026 16:18:00 -0400 CELC O.34685291 http://www.streetinsider.com/Analyst+PT+Change/Celcuity+Inc+%28CELC%29+PT+Raised+to+%24175+at+Guggenheim/26934598.html (Updated - August 17, 2026 7:12 AM EDT) <p>Guggenheim analyst Brad Canino raised the price target on Celcuity Inc (NASDAQ: CELC) to $175.00 (from $165.00) while maintaining a Buy rating.</p><p>The analyst commented: "CELC's update reiterated guidance for Revtorpyk commercial shipments to begin late in the third quarter, and management suggested this achievement could be press released. Since many investors with whom we speak think the company is at risk of missing this guidance, we see that announcement in September as a real potential catalyst for the stock. Our recent physician survey work (LINK) keeps us bullish on the launch trajectory and http://www.streetinsider.com/Analyst+PT+Change/Celcuity+Inc+%28CELC%29+PT+Raised+to+%24175+at+Guggenheim/26934598.html Mon, 17 Aug 2026 07:12:38 -0400 CELC http://www.streetinsider.com/Analyst+Comments/Celcuity+Inc+%28CELC%29+PT+Raised+to+%24175+at+Guggenheim/26934598.html (Updated - August 17, 2026 7:12 AM EDT) <p>Guggenheim analyst Brad Canino raised the price target on Celcuity Inc (NASDAQ: CELC) to $175.00 (from $165.00) while maintaining a Buy rating.</p><p>The analyst commented: "CELC's update reiterated guidance for Revtorpyk commercial shipments to begin late in the third quarter, and management suggested this achievement could be press released. Since many investors with whom we speak think the company is at risk of missing this guidance, we see that announcement in September as a real potential catalyst for the stock. Our recent physician survey work (LINK) keeps us bullish on the launch trajectory and http://www.streetinsider.com/Analyst+Comments/Celcuity+Inc+%28CELC%29+PT+Raised+to+%24175+at+Guggenheim/26934598.html Mon, 17 Aug 2026 07:12:38 -0400 CELC http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Celcuity+Inc+%28CELC%29/26934541.html <p>H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $155.00 price target on Celcuity Inc (NASDAQ: CELC).</p><p>The analyst commented: "On August 13, Celcuity announced 2Q26 results and provided a corporate update. Celcuity disclosed a wholesale acquisition cost of $10,000 per vial, or $30,000 per cycle. Management guided to a gross-to-net of roughly 80%. On coverage, NCCN named the REVTORPYK regimens preferred Category 1 options for wild-type patients in 2L settings. Access work is largely in place, with payer dossiers filed and formulary inclusion underway, against coverage across more than 90% of medical-benefit lives secured ahead of approval. Management does http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Celcuity+Inc+%28CELC%29/26934541.html Mon, 17 Aug 2026 06:42:35 -0400 CELC http://www.streetinsider.com/Analyst+Comments/Celcuity+%28CELC%29+Reiterates+at+Market+Outperform+by+Citizens+Ahead+of+Upcoming+Launch/26933858.html <p>Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $177.00 price target on Celcuity Inc (NASDAQ: CELC).</p><p>The analyst commented, "Celcuity Inc. reported 2Q26 financial results and announced pricing and anticipated grossto-net for REVTORPYK (gedatolisib) ahead of first sales, anticipated in late 3Q26. Celcuity is bringing a second manufacturing site online and following submission of the postapproval supplement to the FDA, anticipates the regulatory aspects to complete prior to the anticipated launch in 3Q26. We maintain our Market Outperform rating and $177 DCF-derived price target ahead of the upcoming launch."</p><p>For an analyst ratings summary and ratings history on Celcuity Inc http://www.streetinsider.com/Analyst+Comments/Celcuity+%28CELC%29+Reiterates+at+Market+Outperform+by+Citizens+Ahead+of+Upcoming+Launch/26933858.html Mon, 17 Aug 2026 04:16:36 -0400 CELC http://www.streetinsider.com/Analyst+PT+Change/Celcuity+Inc+%28CELC%29+PT+Lowered+to+%24150+at+Stifel+as+Gedatolisib+Distribution+Initiated/26924913.html <p>Stifel analyst Stephen Willey lowered the price target on Celcuity Inc (NASDAQ: CELC) to $150.00 (from $175.00) while maintaining a Buy rating.</p><p>The analyst commented, "Management reiterated confidence in its ability to begin shipping commercial product in late-3Q26 and we believe last week’s initiation of the Expanded Access Program – a mechanism to distribute gedatolisib to eligible patients prior to initiating formal commercial shipments – should help with patient on-boarding kinetics (conversion to paid commercial product should be rapid). The now published $30K/month WAC of Revtorpyk yields an unsurprising premium to our prior ~$26K/month launch estimate and management’s incremental provision of http://www.streetinsider.com/Analyst+PT+Change/Celcuity+Inc+%28CELC%29+PT+Lowered+to+%24150+at+Stifel+as+Gedatolisib+Distribution+Initiated/26924913.html Fri, 14 Aug 2026 08:06:30 -0400 CELC http://www.streetinsider.com/Analyst+Comments/Celcuity+Inc+%28CELC%29+PT+Lowered+to+%24150+at+Stifel+as+Gedatolisib+Distribution+Initiated/26924913.html <p>Stifel analyst Stephen Willey lowered the price target on Celcuity Inc (NASDAQ: CELC) to $150.00 (from $175.00) while maintaining a Buy rating.</p><p>The analyst commented, "Management reiterated confidence in its ability to begin shipping commercial product in late-3Q26 and we believe last week’s initiation of the Expanded Access Program – a mechanism to distribute gedatolisib to eligible patients prior to initiating formal commercial shipments – should help with patient on-boarding kinetics (conversion to paid commercial product should be rapid). The now published $30K/month WAC of Revtorpyk yields an unsurprising premium to our prior ~$26K/month launch estimate and management’s incremental provision of http://www.streetinsider.com/Analyst+Comments/Celcuity+Inc+%28CELC%29+PT+Lowered+to+%24150+at+Stifel+as+Gedatolisib+Distribution+Initiated/26924913.html Fri, 14 Aug 2026 08:06:30 -0400 CELC http://www.streetinsider.com/Analyst+PT+Change/Celcuity+Inc+%28CELC%29+PT+Lowered+to+%24140+at+Needham/26924461.html (Updated - August 14, 2026 7:05 AM EDT) <p>Needham analyst Gil Blum lowered the price target on Celcuity Inc (NASDAQ: CELC) to $140.00 (from $157.00) while maintaining a Buy rating.</p><p>The analyst commented: "Following Revtorpyk's approval (note), the drug has secured NCCN inclusion ahead of its late 3Q:26 launch. Celcuity will provide Revtorpyk to select patients through its EAP ahead of launch. The announced pricing is $30k/ cycle WAC (~25% premium to Piqray). Updated mean treatment durations as of August 2026 were 9.0 and 9.7 months for the triplet and doublet in PIK3CA WT patients, respectively (21 months follow-up). Celcuity plans to http://www.streetinsider.com/Analyst+PT+Change/Celcuity+Inc+%28CELC%29+PT+Lowered+to+%24140+at+Needham/26924461.html Fri, 14 Aug 2026 07:05:15 -0400 CELC